Bioisosteric replacement of anilide with benzoxazole: Potent and orally bioavailable antagonists of VLA-4

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 9, 2004, Pages 2331-2334

  Lin, Linus S ^a   Lanza Jr , Thomas J ^a   Castonguay, Laurie A ^a   Kamenecka, Theodore ^a   McCauley, Ermenegilda ^a   Van Riper, Gail ^a   Egger, Linda A ^a   Mumford, Richard A ^a   Tong, Xinchun ^a   MacCoss, Malcolm ^a   Schmidt, John A ^a   Hagmann, William K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANILIDE; BENZIMIDAZOLE DERIVATIVE; BENZOXAZOLE DERIVATIVE; OXYGEN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4 ANTAGONIST;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; LIPOPHILICITY; MOLECULAR MODEL; STEREOCHEMISTRY;

ANILIDES; ANIMALS; BENZOXAZOLES; BIOLOGICAL AVAILABILITY; HYDROGEN BONDING; INTEGRIN ALPHA4BETA1; RATS;

EID: 11144357474     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.01.098     Document Type: Article

References (17)

1. For recent reviews, see: Yang G.X., Hagmann W.K. Med. Res. Rev. 23:2003;369.
2. Tilley J.W., Sidduri A. Drugs Future. 26:2001;985.
3. Holland G.W., Biediger R.J., Vanderslice P. Doherty A.M. Annual Reports in Medicinal Chemistry. Vol. 37:2002;65 Academic, New York.
4. For a review, see: Panes J., Granger D.N. Gastroenterology. 114:1998;1066.
5. 7 antagonists, see: Khandelwal A., Narayanan R., Gopalakrishnan B. Bioorg. Med. Chem. 11:2003;4235.
6. Stasiak M., Mehlin C., Boni E., Vaisar T., Little T., Kim H.-O., Qabar M. Bioorg. Med. Chem. Lett. 11:2003;3875.
7. Doherty G.A., Yang G.X., Borges E., Tong S., McCauley E.D., Treonze K.M., Van Riper G., Pacholock S., Si Q., Koo G.C., Shah K., Mumford R.A., Hagmann W.K. Bioorg. Med. Chem. Lett. 11:2003;1891.
8. Porter J.R., Archibald S.C., Brown J.A., Childs K., Critchley D., Head J.C., Parton T.A., Robinson M.K., Shock A., Taylor R.J., Warrellow G.J. Bioorg. Med. Chem. Lett. 13:2003;805.
9. Hagmann W.K., Durette P.L., Lanza T., Kevin N.J., de Laszlo S.E., Kopka I.E., Young D., Magriotis P.A., Li B., Lin L.S., Yang G., Kamenecka T., Chang L.L., Wilson J., MacCoss M., Mills S.G., Van Riper G., McCauley E., Egger L.A., Kidambi U., Lyons K., Vincent S., Stearns R., Colletti A., Teffera J., Tong S., Fenyk-Melody J., Owens K., Levorse D., Kim P., Schmidt J.A., Mumford R.A. Bioorg. Med. Chem. Lett. 11:2001;2709.
10. Lin L.S., Lanza T., McCauley E., Van Riper G., Kidambi U., Cao J., Egger L.A., Mumford R.A., Schmidt J.A., MacCoss M., Hagmann W.K. Bioorg. Med. Chem. Lett. 12:2002;133.
11. 2+ activated states.
12. For a review of bioisosteres, see: Chen X., Wang W. Doherty A.M. Annual Reports in Medicinal Chemistry. Vol. 38:2003;333 Academic, New York.
13. Dunwell D.W., Evans D. J. Med. Chem. 20:1977;797.
14. Corey E.J., Xu F., Noe M.C. J. Am. Chem. Soc. 119:1997;12414.
15. Sidduri A., Tilley J.W., Lou J.P., Chen L., Kaplan G., Mennona F., Campbell R., Guthrie R., Huang T.-N., Rowan K., Schwinge V., Renzetti L.M. Bioorg. Med. Chem. Lett. 12:2002;2479.
16. Pharmacokinetic studies were performed in male Sprague-Dawley rats with 1 mpk IV or 2 mpk PO administration of the appropriate compound.
17. The value of logD was determined by HPLC at pH 7.3.